Details
New expert insights in transthyretin amyloid cardiomyopathy (ATTR-CM) from ESC Heart Failure Congress 2026 exploring updates in cardiomyopathies https://ow.ly/WuG150Z0iNR
Dr Mathew Maurer and Dr Margot Davis explore emerging evidence, evolving silencer therapies and the ongoing unmet needs shaping the future of ATTR-CM management.
Gain practical perspectives on how new data may influence diagnosis, treatment strategies and long-term clinical decision-making.
This programme is supported by an unrestricted educational grant from AstraZeneca.